- Home
- CZNC vs SLN Comparison
CZNC vs SLN Comparison
Compare CZNC & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CZNC
- SLN
- Stock Information
- Founded
- CZNC 1864
- SLN 1994
- Country
- CZNC United States
- SLN United Kingdom
- Employees
- CZNC N/A
- SLN N/A
- Industry
- CZNC Major Banks
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- CZNC Finance
- SLN Health Care
- Exchange
- CZNC Nasdaq
- SLN Nasdaq
- Market Cap
- CZNC 312.9M
- SLN 268.8M
- IPO Year
- CZNC N/A
- SLN N/A
- Fundamental
- Price
- CZNC $20.02
- SLN $4.51
- Analyst Decision
- CZNC
- SLN Buy
- Analyst Count
- CZNC 0
- SLN 5
- Target Price
- CZNC N/A
- SLN $32.60
- AVG Volume (30 Days)
- CZNC 28.9K
- SLN 53.7K
- Earning Date
- CZNC 10-16-2025
- SLN 11-13-2025
- Dividend Yield
- CZNC 5.59%
- SLN N/A
- EPS Growth
- CZNC 15.34
- SLN N/A
- EPS
- CZNC 1.75
- SLN N/A
- Revenue
- CZNC $108,310,000.00
- SLN $27,169,000.00
- Revenue This Year
- CZNC $5.72
- SLN N/A
- Revenue Next Year
- CZNC $7.18
- SLN N/A
- P/E Ratio
- CZNC $11.47
- SLN N/A
- Revenue Growth
- CZNC 4.96
- SLN 22.28
- 52 Week Low
- CZNC $17.85
- SLN $1.97
- 52 Week High
- CZNC $22.68
- SLN $20.48
- Technical
- Relative Strength Index (RSI)
- CZNC 52.62
- SLN 36.54
- Support Level
- CZNC $19.78
- SLN $4.77
- Resistance Level
- CZNC $20.45
- SLN $5.80
- Average True Range (ATR)
- CZNC 0.40
- SLN 0.39
- MACD
- CZNC -0.04
- SLN -0.03
- Stochastic Oscillator
- CZNC 26.09
- SLN 0.77
About CZNC Citizens & Northern Corp
Citizens & Northern Corp is a community bank operating through its subsidiaries. It provides banking services, including deposit and loan products for personal and commercial customers. The bank also maintains a trust division that provides a wide range of financial services, such as 401(k) plans, retirement planning, estate planning, estate settlements and asset management.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.